Falconer, I'm not greatly savvy on M&A's and corporate amalgamation and somebody with a business background will have to comment in this area. However the options as I see them would run from "hostile takeover" through negotiated buyout to partnership and licensing. The out come would depend on the strength of the companies, actual and potential, strategic market issues, and the moxie off the negotiators. The medium of exchange could be dollars, options, shares and the percentage of future sales and controlling interest in the outcome. You MBA's can elaborate.
If the business deal is not hostile, I think we get a vote in the decision. As far as Anavex, it is obvious that the strength of our negotiating position increases with the success of or drug development.
Probably not much help in answering your questions, Falconer as I am no expert in the mechanics other that what I read in the articles about this happening in the industry. However, I believe that the consensus is that activity will pickup significantly due to the Tax Plan repatriation aspect and the general positive business outlook next year.
News 
Market Data 
Discover 
AI
